IDRI Announces Evolution of Leadership Roles; New Focus on Oncology

February 25th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 25, 2019: After 25 years of success in infectious disease research and development, IDRI is poised to continue to make rapid and significant advances in the battle against the world’s deadliest infectious diseases, while expanding [...]

IDRI Partners with Afrigen Biologics and Biovac to Produce Tuberculosis Vaccine

February 21st, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 22, 2019: In an effort to produce vaccines where they are needed most, IDRI (Infectious Disease Research Institute) is collaborating with the Cape Town, South Africa, based biotechnology startup company Afrigen Biologics, founded by the [...]

Sustainable Squalene Replacement Needed for Pharma

February 12th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 12, 2019: IDRI (Infectious Disease Research Institute) is pleased to announce a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover [...]

IDRI Therapeutic Vaccine for TB to Enter Clinical Trial

February 10th, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Feb. 4, 2019: A clinical trial testing two new therapeutic vaccines, one developed by IDRI (Infectious Disease Research Institute) and another by Archivel Farma, was given the green light to proceed at the inaugural meeting [...]

Temperature-Stable Experimental Tuberculosis Vaccine Enters Clinical Testing

January 23rd, 2019|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Jan. 23, 2019: Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine candidate. The trial is being conducted at the Saint Louis University [...]

IDRI Expands Board of Directors with PwC Partner

December 19th, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Dec. 19, 2018: Gerry McDougall, a Senior Partner at PricewaterhouseCoopers Health Sciences Practice who serves as the company’s Global Health Science Practice Leader, has joined the Board of Directors of IDRI (Infectious Disease Research Institute). [...]

Can New Drugs Be Tested with Computers? Team Explores Possibility for TB Drugs

December 17th, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Dec. 17, 2018: IDRI is partner in a European Union-funded consortium that is focused on demonstrating how advanced computer modelling and simulation can be used to reduce the costs of the clinical trials to test [...]

Merck Fellows Share Skills for Drug Discovery

September 25th, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Sept. 25, 2018: As part of the prestigious Merck Fellowship for Global Health program, IDRI (Infectious Disease Research Institute) is hosting three Fellows in Seattle for three months to assist IDRI scientists in implementing drug [...]

New Diagnostic Test for Leprosy Being Developed

September 19th, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Sept. 19, 2018: Before an infectious disease can be treated, it must be detected. Key attributes of successful diagnostic tests include speed and cost, but it is also critical that they are easy to administer [...]

IDRI Partners with Alexandria Real Estate Equities, Inc. for Summer Internship

July 31st, 2018|Press Releases|

FOR IMMEDIATE RELEASE: Seattle | Aug. 1, 2018: Five years ago, IDRI (Infectious Disease Research Institute) moved into a state-of-the-art lab at 1616 Eastlake Avenue East, which is owned and operated by Alexandria Real Estate Equities, Inc. (NYSE: ARE), in [...]

Load More